Trending...
- House of Buneau Releases "Pretty Boy Heaven," A Cinematic Exploration of Beauty and Distance
- California and European Commission discuss cooperation to accelerate the global transition to a carbon-neutral, resilient, and equitable future
- Mark Dobosz Makes Donorassess.org Free To Every Nonprofit On The Planet
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a virtual fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30, 2022, at 2:15 p.m. EST.
A live webcast of the fireside chat will be available by visiting the Investor Events and Presentations section of atarabio.com. An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.
More on The Californer
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program receiving a CHMP positive opinion for a marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients' lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in Southern California. For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn.
More on The Californer
Contacts
INVESTORS & MEDIA:
Investors
Eric Hyllengren
805-395-9669
ehyllengren@atarabio.com
Media
Alex Chapman
805-456-4772
achapman@atarabio.com
A live webcast of the fireside chat will be available by visiting the Investor Events and Presentations section of atarabio.com. An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.
More on The Californer
- Ukes4Peace Grassroots Movement Brings Community Together Through Music
- California: Governor Newsom proclaims Welcome Home Vietnam Veterans Day 2026
- On the 296th Anniversary of the Ceremony That Made His Ancestor Emperor, a Cherokee Descendant Publishes the Novel That Restores Him
- Appellation St. Helena's 13th Annual bASH Event a Spectacular Display of Wine and Culinary Talent
- PJHM Architects Earns CASH/AIA CA Award of Merit for Design of Corral Hollow Elementary School
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program receiving a CHMP positive opinion for a marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients' lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in Southern California. For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn.
More on The Californer
- NRx Pharmaceuticals Could Be on the Verge of a Breakout Year as AI, FDA Catalysts, and Mental Health Demand Converge
- DC Accounting Firm Offers Free Business CRM to Small Business Clients Alongside Weekly Bookkeeping Model
- CCHR: Psychiatric Drugs Fuel Rising Death Toll: National Adverse Drug Event Awareness Day Confronts America's Medication Crisis
- Explosive $10 Billion Counter-Drone Market with AI-Powered Defense Ecosystem: ZenaTech, Inc. (N A S D A Q: ZENA)
- High-Value Execution Phase Begins: Bitcoin Bancorp Ignites Texas Rollout of Digital Asset ATM Network: Bitcoin Bancorp (Stock Symbol: BCBC) $BCBC
Contacts
INVESTORS & MEDIA:
Investors
Eric Hyllengren
805-395-9669
ehyllengren@atarabio.com
Media
Alex Chapman
805-456-4772
achapman@atarabio.com
Filed Under: Business
0 Comments
Latest on The Californer
- Snell & Wilmer Attorneys Emily Cheung and Kina Wong Appointed Co-Leads of CALA-OC Young Lawyers Cmte
- Long Beach: El Dorado East Regional Park Offers Tips for Visitors on Easter Sunday, April 5
- Classified Employees of the Year Celebrated Across the Ventura County Community College District
- House of Buneau Releases "Pretty Boy Heaven," A Cinematic Exploration of Beauty and Distance
- Bobotails Launches Premium Matching Harness Collections for Small & Medium Breed Dogs
- Homeowner Prep Announces Strategic Language Shift: Replacing "Renters" with "Future Homeowners" to Inspire Wealth-Building Mindsets
- LiposoMore™ Redefines Bioavailability: Joyful Nutritional Launches High-Performance Liposomal Vitamin C and Iron for the Global Supplement Market
- California: Governor Newsom strengthens bans on insider betting by state officials, takes aim at corruption fueled by Trump
- GDE Tree Services Expands Operations into Sydney, NSW
- Tuckwell Machinery Expands CNC Range to Support Australian Cabinet Makers
- "Dave Simmons of StrataX Development: Why AB1033 and SB9 Are About to Rewrite California Real Estate"
- The Inner Power of Emotional Self-Leadership
- Dr. Nadene Rose Shares the Secret to True Success: Faith, Obedience, and Divine Purpose
- California: Governor Newsom signs legislation 3.26.26
- VBO Expands Event Manager 3.0 with Real-Time Sales Visibility, New Dashboards, and Operational Tools
- eBook Publishing Services in USA California Book Publishers Helps Authors Turn Ideas into Successful
- City of Long Beach to Host Recycle Your Bicycle Event on May 2
- Public Employees Are Asking: Are Our Pensions Secure?
- Understanding Unexpected Death: Why Independent Autopsies Matter in Cases Without Clear Cause
- Epic Pictures Group Sets North American Release Date for the Thriller NO ORDINARY HEIST